Clinical Research Trials

Browse trials that we are currently enrolling for by condition and associated pharmaceutical company.

Nonalcoholic Steatohepatitis (NASH)

Viking

VK2809 a phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of VK2809 administered for 52 weeks followed by a 4-week off-drug phase in subjects with biopsy proven non-alcoholic steatohepatitis with fibrosis(stage 1-3).

Learn More

Galactin

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis.

Learn More

Crohn’s

Eli Lilly(AMAM)

This is a Phase 3, multicenter, randomized, double-Blind, placebo- and active- controlled, treat-through study to evaluate the efficacy and safety of mirikizumab in subjects who have moderately to severely active Crohn’s disease. Participants were divided into three study arms: the experimental group received intravenous (IV) and subcutaneous (SC) injections of mirikizumab; the group in the active comparator group received IV and SC injections of ustekinumab; the subjects in the placebo comparator group received placebo IV and SC injections.

Learn More

Arena(cultivate)

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects With Moderately to Severely Active Crohn’s Disease.

Learn More

Screening Colonoscopy

Guardant

The GuardantLUNAR-2 test is an NGS-based plasma assay which derives a binary qualitative result for a patient’s risk of colorectal cancer.  No results from the test will be returned to either the patient or the investigator and therefore no treatment decisions will be based upon the results.

Learn More

Ulcerative Colitis

Eli Lilly (AMBI)

The purpose of this study is to evaluate if study drug mirikizumab is safe and effective compared to vedolizumab and placebo in participants with moderately to severely active ulcerative colitis (UC).

Learn More

Suzhou

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC). CBP-307 capsules are administered orally. This study includes stage 1 and stage 2. After screening, subjects will enter the randomized, double-blind, placebo-controlled induction therapy for 12 weeks, i.e., the study stage 1. All subjects who complete 12 weeks of induction therapy (with CBP-307 or placebo) in the study stage 1 and complete all examinations (including colonoscopy) at the week 12 visit can choose to enter the study stage 2 of a total of 40 weeks, including 36 weeks of continuous administration and 4 weeks of safety follow-up after the last dose.

Learn More

Eosinophilic Esophagitis

Arena 206

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.

Learn More

The physicians at Digestive Healthcare of Georgia are closely monitoring the coronavirus (COVID-19) outbreak. In the interest of everyone’s health and safety we ask all patients and their guests who have a fever (100° or above), symptoms of a respiratory infection, or who may have traveled to a restricted country or may have been exposed to a person with known COVID-19, the flu or any other communicable disease to reschedule their appointments or procedures. You will not be charged for canceling/rescheduling your appointment. We will be following CDC and Georgia Department of Public Health’s recommendations for screening and management of patients. If you are at all concerned you may have a serious infectious disease, your best course of action is to seek care at your primary care physician’s office or local hospital’s emergency department.

We have implemented a telemedicine visit for our patients who are unable to be in the office for their appointment. Please call our office to schedule a telemedicine visit with your provider.